1. Home
  2. XBIO vs SVRE Comparison

XBIO vs SVRE Comparison

Compare XBIO & SVRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xenetic Biosciences Inc.

XBIO

Xenetic Biosciences Inc.

HOLD

Current Price

$4.33

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Logo SaverOne 2014 Ltd.

SVRE

SaverOne 2014 Ltd.

HOLD

Current Price

$2.60

Market Cap

6.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIO
SVRE
Founded
N/A
2014
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
6.2M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
XBIO
SVRE
Price
$4.33
$2.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
33.7K
39.3K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
38.52
N/A
EPS
N/A
N/A
Revenue
$2,976,411.00
N/A
Revenue This Year
$2.81
$1,793.31
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.04
N/A
52 Week Low
$1.90
$0.55
52 Week High
$13.93
$6.30

Technical Indicators

Market Signals
Indicator
XBIO
SVRE
Relative Strength Index (RSI) 56.96 37.57
Support Level $2.61 $2.02
Resistance Level $4.90 $3.33
Average True Range (ATR) 0.29 0.30
MACD -0.04 -0.02
Stochastic Oscillator 31.72 14.04

Price Performance

Historical Comparison
XBIO
SVRE

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

About SVRE SaverOne 2014 Ltd.

Saverone 2014 Ltd is engaged in the design, development, and commercialization of transportation and safety solutions, designed to prevent car accidents based on its patented technology of detecting, analyzing, and locating cellular phone radio frequency, or RF signals. The company is developing two product lines: the first is an In-Cabin Driver Distraction Prevention Solution (known as SaverOne system), or DDPS; and the second is an Advanced Driver-Assistance System, or ADAS, product that detects vulnerable road users, or VRUs, and provides a warning to the vehicle regarding potential collision. Geographically, Saverone generates maximum revenue from Europe and the rest from Israel.

Share on Social Networks: